Verrica Pharmaceuticals Reports 54% Revenue Decline and $13.2 Million Net Loss in Q2 2026

Verrica Pharmaceuticals Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $5.9 million, a decrease of 54% compared to $12.7 million in the same period last year. The decline was primarily driven by a significant drop in license and collaboration revenue, which fell to $0.8 million from $8.2 million in the prior year, largely due to the absence of milestone payments from its collaboration with Torii. In contrast, product revenue from its approved drug, YCANTH (VP-102), increased to $5.1 million from $4.5 million, reflecting higher delivery volumes to distribution partners.

Operating expenses for the quarter rose to $19.0 million, up from $11.2 million in the previous year, marking a 69% increase. This rise was attributed to higher research and development costs, which surged to $6.0 million from $1.8 million, as the company advanced its clinical programs. Selling, general, and administrative expenses also increased to $10.3 million, up from $8.9 million, driven by expanded commercial activities and sales force growth. The net loss for the quarter was $13.2 million, compared to a net income of $204,000 in the same quarter of 2025.

As of June 30, 2026, Verrica's total assets stood at $36.0 million, a decrease from $47.1 million at the end of 2025. The company's cash reserves dropped to $11.2 million from $30.1 million, while total liabilities increased to $31.7 million, up from $22.4 million. The accumulated deficit reached $347.7 million, reflecting ongoing operational losses since the company's inception. The company has indicated substantial doubt regarding its ability to continue as a going concern within the next year, given its current cash position and the need for additional funding.

Strategically, Verrica has made significant moves, including the FDA approval of YCANTH in July 2023 for treating molluscum contagiosum, and the establishment of a wholly-owned subsidiary in Ireland to facilitate regulatory filings in the European Union. The company also entered into a distribution agreement with Medomie Pharma Ltd. in July 2026, granting exclusive rights to commercialize YCANTH in Israel. Furthermore, on August 3, 2026, Verrica secured a credit agreement providing up to $27.5 million in funding, which includes an initial $12.5 million available immediately.

Looking ahead, Verrica plans to continue its focus on expanding the commercialization of YCANTH and advancing its clinical programs for common warts and VP-315, a treatment for basal cell carcinoma. The company aims to secure additional capital through equity offerings, debt financing, and strategic partnerships to support its ongoing operations and development activities. However, the uncertainty surrounding future funding and market conditions poses challenges to its growth trajectory.